Drug Updates

Skip to main content

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure

Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis

Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2014

Drug Updates, Payers' Guide

Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes

Drug Updates, Payers' Guide

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh

Drug Updates, Payers' Guide

Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer

Drug Updates, Payers' Guide

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Drug Updates, Payers' Guide

Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh

2
3
4
5
6
7
8

Page 5 of 8
Results 41 - 50 of 80